AbbVie Inc. (ABBV) stock analysis
Healthcare · Drug Manufacturers - General
From the 10-K filed 2026-02-20
Business type: Franchise
How it makes money
It generates net revenues of $61.2 billion primarily from immunology products, with Skyrizi and Rinvoq together accounting for 42% of the total.
The business relies on a single global segment focused on high-margin biologics and JAK inhibitors. These therapies treat chronic autoimmune and inflammatory conditions, which ensure recurring demand as patients require ongoing dosing to manage their diseases.
Sales are made to wholesalers, specialty pharmacies, and government agencies. Outside the United States, it works through centralized national payer systems to secure reimbursement terms for its specialized medical treatments.
What protects it: the moat
It maintains market exclusivity for its therapies through patents and regulatory barriers that prevent lower-priced generic or biosimilar versions from entering the market.
Intellectual property is the primary mechanism for preserving high margins. These patents provide a period of market exclusivity that is essential for profitability in the United States and other major global markets.
The complexity of biologic products like Skyrizi acts as a secondary barrier, as competitors must navigate long regulatory pathways and clinical requirements to approve biosimilars that can challenge its market share.
What growth costs
It incurred $7.4 billion in intangible asset amortization and $6.5 billion in contingent consideration changes while funding all stages of its R&D pipeline.
Growth requires constant reinvestment to replace revenue lost to future patent expirations. It funds an extensive pipeline across immunology, neuroscience, and oncology while integrating external innovations from acquisitions.
Its cost structure includes significant charges for past acquisitions, reflected in the amortization of acquired assets and adjustments to the estimated value of future payments owed to partners for successful clinical milestones.
What could damage it
The loss of patent protection for Skyrizi or Rinvoq could allow biosimilars to enter the market and rapidly reduce revenue for those products.
Because two products account for 42% of total revenue, a successful legal challenge to its patents or the expiration of market exclusivity would lead to immediate generic competition. This typically results in a significant reduction in sales within a short amount of time, impairing the company's ability to fund its operations and dividends.
About AbbVie Inc.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.